Medical Devices

A landmark report reveals a crisis: 91% of biopharma firms lack the data maturity for AI, undermining patient care and stalling innovation.

Blue Faery recognizes two doctors whose groundbreaking research in immunotherapy and targeted drugs has created new standards of care for liver cancer patients.

Amid industry-wide financial strain, Kurin's simple device for preventing blood culture contamination delivers record growth by saving hospitals money and lives.

A wound care gel recall by Blaine Labs reveals a history of contamination issues and prior FDA warnings, posing serious risks to vulnerable patients.

USF lands 42 graduate programs in the top 100, with its medical school earning a Tier 1 research rating, cementing its role as a national powerhouse.

A new certification for AI-guided cardiac ultrasound seeks to solve the training and trust gap, making crucial heart scans more accessible for frontline providers.

Following positive safety data, Phanes Therapeutics expands trials for spevatamig, a first-in-class antibody targeting two cancer pathways at once.

Lupin wins FDA approval for its generic dapagliflozin, a move set to slash costs for a blockbuster diabetes and heart drug and reshape patient care.

After three rejections, Outlook Therapeutics escalates its fight for US approval of a key wet AMD drug, already sold in Europe. Will the FDA bend?

A new minimally invasive stent for complex aortic arch disease receives FDA approval, offering hope to high-risk patients previously deemed untreatable.

FDA approves a pivotal trial for a novel heart valve, potentially revolutionizing treatment for millions with severe tricuspid regurgitation.

A NJ surgeon performed the nation's first robotic-assisted shoulder replacement in an outpatient setting, heralding a new era of surgical precision.

A new bispecific antibody aims to treat the 50% of AxSpA patients who find no relief, as Fortitude Biomedicines enters a competitive autoimmune market.

Ontario and Quebec expand public coverage for a potent cholesterol drug, offering a critical lifeline to thousands at risk of a second cardiovascular event.

As employers face staggering GLP-1 expenses, a new program aims to deliver measurable outcomes by integrating clinical support directly into pharmacy benefits.

A new poll shows two-thirds of workers are more likely to use GLP-1s with employer coverage, highlighting the role of cost, support, and stigma.

Life Sciences Ontario's new board appointments signal a strategic shift, bringing in leaders from medtech, agri-tech, pharma, and nuclear isotopes.

Backed by a $41.3M ARPA-H award, SonoNeu is pioneering sonogenetics, a non-invasive therapy using ultrasound to control cells and treat nerve pain.

With new clinical trial data showing its AI is superior for complex AFib, Volta Medical heads to a major conference to change the standard of care.

A new AI software that analyzes MRI scans has received a first-of-its-kind FDA classification, promising to help doctors differentiate complex brain disorders.